Nicox is on track to file for approval of its NCX 470 therapy for eyesight-robbing disease glaucoma after it showed efficacy in a second pivotal trial. The positive data from the Phase 3 Denali trial ...

NCX 470 New Drug Application (NDA) filing in the United States: expected in H1 2026. NCX 470 New Drug Application (NDA) filing in China: expected after submission in the U.S. Results from NCX 470 ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that once daily dosing of NCX 470 0.1%, a novel nitric oxide (NO)-donating bimatoprost ...

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive Japanese partner, Kowa, has initiated a Phase 3 safety clinical trial ...

(RTTNews) - Nicox SA announced the signing of a new agreement concerning NCX 470 with Kowa, a Japanese company. The agreement, worth up to 191.5 million euros, grants Kowa exclusive rights to develop ...

The Alternative Bank has announced a strategic partnership with the Nigeria Commodity Exchange aimed at unlocking greater value across the agricultural value chain through a structured, ...

Generally, a 10% to 30% down payment is required on the on-road price of a vehicle. However, the exact details regarding EMI, down payment, zero percent interest, loan tenure, and the overall ...

(RTTNews) - Nicox SA announced the results of the Whistler Phase 3b exploratory clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in ...